Background: Newer diabetes medications may have beneficial effects on mortality,
cardiovascular outcomes, and renal outcomes. Purpose: To evaluate the effectiveness …

Introduction The evolution of treatment for diabetic nephropathy illustrates how basic
biochemistry and physiology have led to new agents such as SGLT2 inhibitors and …

Abstract Treatment with glucagon-like peptide-1 receptor agonists (GLP1-RA) in patients
with type 2 diabetes (T2D) and chronic kidney disease (CKD) may attenuate kidney disease …

Glucagon-like peptide-1 receptor agonists are an emerging class of medications
transforming the management of diabetes mellitus and obesity, two highly prevalent and …

During the last decade, the landscape of type 2 diabetes (T2D) management has been
completely transformed, moving from a glucose-centric perspective to a holistic approach …

Objective To compare the effectiveness of three commonly prescribed oral antidiabetic
drugs added to metformin for people with type 2 diabetes mellitus requiring second line …

Background CKD is a serious diabetes-related complication. While guidelines recommend
use of sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 …

Background: Chronic kidney disease (CKD) is a serious diabetes-related complication.
While guidelines recommend use of sodium-glucose co-transporter 2 (SGLT2) inhibitors and …

GLP-1 receptor agonism is a promising therapy for slowing the progression of diabetic
chronic kidney disease. Recent studies support kidney benefits GLP-1 receptor agonists …

The presence of insulin resistance is associated with a greater risk of albuminuria, kidney
damage and progression to kidney failure in epidemiologic studies. Increased waist …